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Cardiotoxicity has been extensively reported in venlafaxine (VEN) overdoses. Asthenia is also among the common side effects
described for this antidepressant. VEN is metabolized mainly by CYP2D6 and to a minor extent by CYP2C19 to the major active
metabolite O-desmethylvenlafaxine (ODV). Altered pharmacokinetic parameters in patients with polymorphisms in the CYP2D6
and CYP2C19 genes that result in decreased enzymatic activity have been documented. Here we describe a patient case of VEN
associated palpitations and asthenia.The patient takes VEN extended release 150mg twice daily. Genotyping confirmed the patient
is a poor metabolizer for CYP2D6 and an intermediate metabolizer for CYP2C19. We propose that the palpitations and asthenia
are related to sustained VEN exposure due to reduced metabolism.
1. Introduction
VEN is a serotonin-norepinephrine reuptake inhibitor
(SNRI) prescribed to treat depression [1]. VEN is also used
off label for the treatment of posttraumatic stress disorder
(PTSD) [2, 3]. Among adverse events reported for this
medication, asthenia appears to occur in at least 10% of the
patients [4]. Cases of VEN toxicity are associated with QTc
prolongation and other cardiovascular presentations [5, 6].
VEN is mainly eliminated via the CYP enzyme system with
CYP2D6 and CYP2C19 being themain enzymes involved [7].
Patients with impaired VEN metabolism especially CYP2D6
reduced activity can result in supratherapeutic serum lev-
els of VEN, placing the patient at high risk for adverse
effects [8–10]. Furthermore, fatal poisoning due to significant
reduction of metabolic capacity in CYP2D6 and CYP2C19
enzymes has also been documented in the literature [11].
The deceased (a 34-year-old Caucasian male) was taking
venlafaxine XR 150mg twice daily. Genotyping revealed the
subject has CYP2D6 (∗4/∗5; 1 gene copy) and CYP2C19
(∗2/∗2) which corresponded to poor metabolizer phenotype
for both enzymes. Serum level of VENwas extremely elevated
and the concentrations of its metabolites were altered as a
result of the reduced activity of CYP2D6 and CYP2C19. It
seems that the deceased had elevated VEN blood levels for a
prolonged period of time before cardiac arrest happened.The
authors concluded that the unintended death of the subject
could be attributed to the impaired metabolism of VEN [11].
In the light of these reports, we present a patient case of severe
asthenia and palpitations associated with the use of VEN
in a CYP2D6 poor metabolizer and CYP2C19 intermediate
metabolizer.
2. Case Presentation
The patient is a 58-year-old Caucasian male with a history
of depression and complex posttraumatic stress disorder
(PTSD) that presented for a medical therapy management
(MTM) consult. The patient expressed feeling intermittent
palpitations associated with exertional dyspnea and added
that he had been experiencing asthenia and lack of endurance
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since early childhood; however his fatigue symptoms wors-
ened when he started VEN around twelve years ago. The
patient was treated for bipolar disorder, which he believes
was misdiagnosed. Additionally, he disclosed that many of
the factors contributing to his PTSD in the past are no longer
present and for these reasons he has been weaned off from
some of the medications prescribed for bipolar disorder and
PTSD. Patient’s current medications are as follows: venlafax-
ine XL 150mg twice daily, adalimumab 40mg every 15 days,
and lamotrigine 125mg daily. He described his weakness as
being unable to do any type of physical activity for a prolong
period of time and he experiences pain in his calves by just
standing. Contributing to his fatigue, the patient has a history
of ankylosing spondylitis.The patient was recently started on
coenzyme Q10 400mg daily and L-carnitine 300mg daily by
the referring physician to aid with his fatigue prior to the
MTM consult. He has no history of diabetes, dyslipidemia,
or hypertension.
3. Medical Evaluation
On clinical examination, the palpitations were not associated
with QTc prolongation (QTc = 443msec). Electrocardiogram
(holter) examination revealed symptoms of skipped beats
and heart racing which were associated with sinus rhythm
and occasional premature atrial beats. He was in sinus
tachycardia at 101 beats per minute with normal intervals
and normal axis. There were no other abnormalities. He has
no associated syncope or presyncope. He also underwent a
dobutamine stress test. His ejection fraction response was
from 60% at rest to 80% at peak stress. Peak heart rate was
150 bpm, which was 93% of the maximum predicted heart
rate. His hemoglobin A1C was borderline elevated at 5.5%;
blood glucose was 111mg/dL (normal). Blood urea nitrogen,
creatinine, and urinary profile were all within normal limits.
Antinuclear antibodies and other immunology blood testing
were unremarkable. Patient’s alpha-tocopherol was elevated
at 24.9mg/L. Also serum calcium level was slightly elevated
at 10.3mg/dL. Vitamin D levels were not available; however a
pelvic X-ray suggested normal bone mineral density.
4. Pharmacogenomic Analysis
Genomic testing was performed from a buccal swab sample
using a commercial laboratory. Briefly, genomic DNA was
isolated from a buccal swab and the relevant genomic regions
were amplified by polymerase chain reaction. Analysis of
CYP1A2, CYP2B6, CYP2C19, CYP3A4, andOPRM1was com-
piled using a custom xTAG assay (Luminex Molecular Diag-
nostics). Analysis of CYP2D6 was completed using xTAG
kits. The following genetic variants can be observed using
this assay: CYP1A2: −3860G>A, −2467>delT, −739T>G,
−729C>T, −163C>A, 125C>G, 558C>A, 2116G>A, 2473G>A,
2499A>T, 3497G>A, 3533G>A, 5090C>T, 5166G>A, and
5347C>T; CYPB6: ∗1, ∗4, ∗6, and ∗9; CYP2C19: ∗1, ∗2, ∗3,
∗
4, ∗5, ∗6, ∗7, ∗8, and ∗17; CYP2C9: ∗1, ∗2, ∗3, ∗4, ∗5,
and ∗6; CYP2D6: ∗1, ∗2, ∗2A, ∗3, ∗4, ∗5, ∗6, ∗7, ∗8, ∗9,
∗10, ∗11, ∗12, ∗14, ∗15, ∗17, and ∗41, gene duplication;
CYP3A4: ∗1, ∗13, ∗15A, and ∗22; OPRM1 118A>G. The
patient carried CYP2D6 ∗4/∗9 and CY2C19 ∗1/∗2 consistent
with poor CYP2D6 metabolizer and intermediate CYP2C19
metabolizer phenotypes.
5. Antidepressant and Pharmacogenomics
Driven Recommendations
Patient’s genetic test results established a phenotype of
CYP2D6 poor metabolizer and CYP2C19 intermediate
metabolizer. Due to reports of cardiotoxicity in VEN over-
dose and in poor metabolizer patients [12, 13], our rec-
ommendations included switching the patient to alternative
agents. Antidepressants with alternative metabolic pathways
were considered. One of the recommended options was
desvenlafaxine, a synthetic form of ODV which is a US
Food and Drug Administration (FDA) approved medication
in the treatment of depression [14, 15]. Desvenlafaxine was
recommended sincemetabolism does not involve catalysis by
CYP2D6 [16]. Other alternatives considered were sertraline
or citalopram based on recommendations published by Swen
et al. [17]. Additional suggestions were given to gradually tap-
per down the patient from VEN based on recommendations
published by Shelton [18].
6. Discussion
It has been suggested that cardiotoxicity can be expected
in patients on VEN and with poor metabolism in the
CYP2D6 enzyme [12, 13]. VEN is metabolized to O-
desmethylvenlafaxine (ODV) mainly by CYP2D6 [19, 20],
but it can also be metabolized by CYP2C19 [20]. ODV is
an active metabolite with similar pharmacological activity
as the parent drug VEN and a half-life of about 10 hours
[15, 21].The target therapeutic concentration in serum for the
sum of VEN + ODV ranged between 195 and 400 𝜇g/L [8];
however lower concentration ranges have also been suggested
(125 and 400 𝜇g/L) [22]. ODV undergoes further demethyla-
tion to N,O-didesmethylvenlafaxine (NODV) mediated via
CYP3A4 and CYP2C19. Additionally, VEN can undergo
N-demethylation to form N-desmethylvenlafaxine (NDV)
catalyzed by CYP3A4 and CYP2C19 [7]. NDV, a minor
metabolite, has been associated with weak norepinephrine
and serotonin reuptake inhibition [21]. VEN elimination is
mainly through urinary excretion (85%) [23]. Elimination
entails biotransformation to ODV. Unconjugated and conju-
gated ODV (29% and 26%, resp.) are the major metabolites
excreted in urine. However, 27% of other minor inactive
metabolites are also found [24]. NDV is found in about 1%
and only 4.7% of unchanged VEN appear in human urine
[21, 23]. CYP2D6 poor metabolizers (PMs) have shown a
significant decrease in oral clearance compared to extensive
metabolizers (EMs). CYP2D6PMs exhibit higherVEN, lower
ODV, higher NDV plasma concentrations, and lower ratio
of ODV/VEN compared to EMs [8–10, 12, 25]. Our patient
was consistent with poor and intermediate metabolizer of
CYP2D6 and CYP2C19, respectively. Even though serum
levels of VEN,ODV, orNDV in the patient were not obtained,
Case Reports in Genetics 3
high levels of VEN, low levels of ODV, and high levels of
NDV are expected in this patient based on previous reports
[8–10]. The patient is taking a high dose of the extended
release formulation. The recommended maximal dose for
depression is 225mg/day but doses up to 300mg/day have
been administered for the off-label use of PTSD [2, 3]. We
posit that the impaired metabolism of VEN and the high
dose of medication that the patient is receiving can place
the patient at increased risk of experiencing side effects.
Multiple reports of cardiotoxicity have been documented in
the literature with the use of VEN (palpitations, shortness of
breath, proarrhythmias, andQT interval prolongation) [5, 12,
26]. In a study comparing VEN overdose to overdoses caused
by other antidepressants, VEN was significantly associated
with higher heart rate (𝑃 < 0.0001) [27]. Our patient
presented mild tachycardia upon evaluation (HR = 101 bpm).
Also of concern, the patient reported a previous history ofQT
interval prolongation (resolved). Patient QTc was 443msec
which is close to the accepted upper limit of 450msec in
adultmales [28]. A similar pattern was observed in a previous
electrocardiogram (holter) performed over 12 years ago in
this patient. It is not clear from patient’s record whether the
patient was taking VEN at that time. The possibility that
adalimumab might have a role in the mild tachycardia the
patient is experiencing cannot be discarded. Palpitation has
been also reported in less than 5% of the patients that take
adalimumab [29]. However, we propose that the elevated
heart rate is associated with high levels of VEN due to the
impaired metabolism. No significant drug-drug interactions
were found with patient’s concomitant medications. Neither
lamotrigine nor adalimumab are metabolized by the CYP450
enzymes. Lamotrigine is mainly metabolized via glucuronic
acid conjugation [30] and adalimumab seems to be removed
by opsonization via the reticuloendothelial system [31].
Therefore additional impact on VENmetabolism due to drug
interactions is not anticipated.
The patient also is experiencing severe asthenia. Even
though our patient has a significant past medical history
of weakness and fatigue, the patient reported worsening
of his symptoms after VEN initiation. Several reports of
asthenia in patients on VEN have been published [4, 32–
35]. Asthenia has also been reported in low frequency in
patients taking lamotrigine [30]. However, it is not clear
whether it is contributing to patient’s symptoms. It is more
likely that the patient is experiencing worsening of asthenia
and cardiovascular symptoms as a result of accumulation of
VEN.The accumulation is related to impairedmetabolism by
CYP2D6 and CYP2C19 to some extent and the high dose of
VEN. Favoring our hypothesis, a fatal drug poisoning case
in a patient that was poor metabolizer for both CYP2D6
and CYP2C19 was published by Jornil et al. [11]. The authors
attributed the unintended death of the subject to VEN high
concentration as a result of the reduced metabolic capacity.
There are significant similarities of this case to our patient
that are worth highlighting: VEN high dose (150mg twice
daily) of extended release formulation and impaired activity
of CYP2D6. Even though our patient was not a CYP2C19 PM,
it is arguable that our patient might have some reduction in
the activity of the CYP2C19 enzyme. Based on this forensic
case and previous reports in CYP2D6 poor metabolizers, it
is tempting to state that our patient is experiencing severe
asthenia and palpitations as a result of high plasma levels of
VEN due to impaired metabolism. It would be necessary to
obtain serum levels for VEN, ODV and NDV to confirm.
Unfortunately, these levelswere not available and this remains
a limitation of this study.
In summary, we present a case of severe asthenia and pal-
pitations. VEN appears to be associated with these side effects
in a CYP2D6 poor and CYP2C19 intermediate metabolizer.
Several studies mentioned in this report have suggested
cardiotoxicity associated with VEN overdose and in CYP2D6
poor metabolizers. This report supports the clinical utility
of determining a patient’s genotype in order to optimize
patient therapy by choosing optimal agents and preventing
side effects or toxicity. Finally, the involvement of a pharma-
cist with expertise in pharmacogenomics can be helpful in
guiding adjustments based on these increasingly recognized
“gene-drug” interactions.
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